Rallybio Corporation
General ticker "RLYB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $34.1M (TTM average)
Rallybio Corporation follows the US Stock Market performance with the rate: 47.3%.
Estimated limits based on current volatility of 1.2%: low 15.78$, high 16.17$
Factors to consider:
- Earnings expected soon, date: 2026-08-06 bmo
- Total employees count: 14 (-44.0%) as of 2025
- Top business risk factors: Product development failure, Regulatory and compliance, Clinical trial failure, Market competition, Labor/talent shortage/retention
- Current price 43.2% above estimated high
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.78$, 11.13$]
- 2026-12-31 to 2027-12-31 estimated range: [2.78$, 8.54$]
Financial Metrics affecting the RLYB estimates:
- Positive: with PPE of -3.4 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -92.22 <= 0.30
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 146.21 > -0.65
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: -0.15 < Industry inventory ratio change (median), % of 0
Short-term RLYB quotes
Long-term RLYB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.64MM | $0.86MM |
| Operating Expenses | $78.93MM | $61.13MM | $33.92MM |
| Operating Income | $-78.93MM | $-60.50MM | $-33.06MM |
| Non-Operating Income | $6.41MM | $4.96MM | $24.96MM |
| R&D Expense | $53.54MM | $41.51MM | $19.60MM |
| Income(Loss) | $-72.52MM | $-55.54MM | $-8.10MM |
| Other Income(Loss) | $0.00MM | $-2.24MM | $-0.87MM |
| Net Income(Loss)* | $-72.52MM | $-57.77MM | $-8.98MM |
| Stockholders Equity | $106.18MM | $61.65MM | $57.96MM |
| Assets | $115.62MM | $68.11MM | $62.26MM |
| Operating Cash Flow | $-60.27MM | $-49.28MM | $-29.81MM |
| Capital expenditure | $0.01MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $27.66MM | $33.49MM | $47.27MM |
| Financing Cash Flow | $0.14MM | $5.20MM | $0.02MM |
| Earnings Per Share** | $-14.34 | $-10.61 | $-1.59 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.